Common * Rash occurs in the majority of patients. This resembles acne and primarily involves the face and neck. It is self-limited and resolves in the majority of cases, even with continued use. Some clinical studies have indicated a correlation between the severity of the skin reactions and increased survival though this has not been quantitatively assessed. The Journal of Clinical Oncology reported in 2004 that "cutaneous skin rash seems to be a surrogate marker of clinical benefit, but this finding should be confirmed in ongoing and future studies." The newsletter Lung Cancer Frontiers reported in its October 2003 issue, "Patients with moderate to severe cutaneous reactions rashes have a far better survival, than those with only mild reactions and much better than those with no cutaneous manifestations of drug effects." * Diarrhea * Loss of appetite * Fatigue * Partial hair loss (by strands, not typically in clumps) Rare * interstitial pneumonitis, which is characterized by cough and increased dyspnea. This may be severe and must be considered among those patients whose breathing acutely worsens. * ingrown hairs, such as eyelashes * gastrointestinal tract toxicity * serious or fatal gastrointestinal tract perforations * skin toxicity * bullous, blistering, and exfoliative skin conditions (some fatal) * Stevens–Johnson syndrome/toxic epidermal necrolysis * ocular disorders * corneal lesions * Pulmonary toxicity * interstitial pneumonitis * bronchiolitis obliterans with organizing pneumonia (BOOP) * pulmonary fibrosis * fatal asymmetric interstitial lung disease
Erlotinib
Nilotinib
Afatinib
Axitinib
Sunitinib
Icotinib
Crizotinib
Tepotinib